We are live on
!
Find out more
N
Nuveen Portfolio holdings
AUM
$369B
1-Year Est. Return
31.66%
This Fund
S&P 500
This Quarter
Est. Return
-2.85%
1 Year Est. Return
+31.66%
3 Year Est. Return
+110.02%
5 Year Est. Return
+148.02%
10 Year Est. Return
+492.84%
AUM
$247B
AUM Growth
-$11.7B
(-4.5%)
Cap. Flow
-$1.08B
Cap. Flow
% of AUM
-0.44%
Top 10 Holdings %
Top 10 Hldgs %
21.96%
Holding
3,327
New
107
Increased
1,095
Reduced
1,938
Closed
58
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$3.11B |
| 2 |
iShares Russell 1000 Growth ETF
IWF
|
+$300M |
| 3 |
Baxter International
BAX
|
+$237M |
| 4 |
American Tower
AMT
|
+$196M |
| 5 |
UnitedHealth
UNH
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$343M |
| 2 |
Meta Platforms (Facebook)
META
|
+$300M |
| 3 |
Microsoft
MSFT
|
+$294M |
| 4 |
Salesforce
CRM
|
+$266M |
| 5 |
Match Group
MTCH
|
+$248M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.83% |
| 2 | Healthcare | 15.1% |
| 3 | Financials | 12.26% |
| 4 | Consumer Discretionary | 11.08% |
| 5 | Industrials | 8.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Gilead Sciences
GILD
$165B
| $493M | 0.2% |
7,991,520
+1,123,549
| +16% | +$70.8M |
|
|
102
iShares Russell 1000 Growth ETF
IWF
$128B
| $490M | 0.2% |
9,308,552
+5,101,700
| +121% | +$300M |
|
103
Adobe
ADBE
$104B
| $489M | 0.2% |
1,776,340
-8,238
| -0.5% | -$3.12M |
|
104
Target
TGT
$66.6B
| $488M | 0.2% |
3,291,551
-115,208
| -3% | -$18.4M |
|
105
Fidelity National Information Services
FIS
$22.1B
| $484M | 0.2% |
6,399,413
+246,537
| +4% | +$23M |
|
106
T-Mobile US
TMUS
$190B
| $481M | 0.19% |
3,584,566
-1,072,220
| -23% | -$151M |
|
|
WCN
107
Waste Connections
WCN
$42.3B
| $476M | 0.19% |
3,525,467
-92,281
| -3% | -$12.6M |
|
108
CVS Health
CVS
$122B
| $472M | 0.19% |
4,954,072
-60,930
| -1% | -$6.03M |
|
109
Edwards Lifesciences
EW
$51.6B
| $460M | 0.19% |
5,561,148
-1,048,938
| -16% | -$101M |
|
110
Humana
HUM
$44.4B
| $455M | 0.18% |
938,378
-38,868
| -4% | -$18.9M |
|
111
Blackrock
BLK
$177B
| $450M | 0.18% |
818,333
+1,230
| +0.2% | +$805K |
|
112
IBM
IBM
$221B
| $444M | 0.18% |
3,739,993
-614,061
| -14% | -$80.6M |
|
|
HZNP
113
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $430M | 0.17% |
6,954,570
-41,263
| -0.6% | -$2.88M |
|
114
Intel
INTC
$510B
| $427M | 0.17% |
16,563,996
-2,270,047
| -12% | -$77.4M |
|
115
Crown Holdings
CCK
$13.1B
| $425M | 0.17% |
5,239,145
+43,471
| +0.8% | +$4.05M |
|
116
Equinix
EQIX
$105B
| $424M | 0.17% |
745,842
-5,075
| -0.7% | -$3.32M |
|
117
PNC Financial Services
PNC
$99.9B
| $416M | 0.17% |
2,783,926
-3,380
| -0.1% | -$548K |
|
118
Trane Technologies
TT
$106B
| $415M | 0.17% |
2,863,785
+119,444
| +4% | +$17.8M |
|
119
Boston Scientific
BSX
$71.5B
| $409M | 0.17% |
10,552,928
+1,036,331
| +11% | +$41.6M |
|
120
AstraZeneca
AZN
$251B
| $409M | 0.17% |
3,725,839
-37,423
| -1% | -$4.75M |
|
121
MetLife
MET
$62.8B
| $408M | 0.17% |
6,714,845
+582,095
| +9% | +$37.2M |
|
|
122
Baxter International
BAX
$13.8B
| $407M | 0.16% |
7,554,781
+3,941,371
| +109% | +$237M |
|
123
Sherwin-Williams
SHW
$89.6B
| $403M | 0.16% |
1,970,152
-172,498
| -8% | -$40.9M |
|
124
Public Storage
PSA
$61.1B
| $395M | 0.16% |
1,349,319
-48,772
| -3% | -$15.9M |
|
125
Uber
UBER
$150B
| $392M | 0.16% |
14,783,988
+1,122,552
| +8% | +$31M |
|
Similar funds
VFT
Nuveen's Q3 2022 Portfolio in Review
As of Q3 2022, Nuveen held 3,327 positions worth $247B, down 4.5% from $259B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Trading was light in Q3 2022: portfolio turnover was 5%. Nuveen opened 107 new positions and exited 58, leaving the 3,327-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 24% a quarter earlier, followed by Healthcare and Financials.
- Nuveen's largest Q3 2022 buy was Alibaba: 1,014,906 shares worth $81.2M.
- Nuveen added most to Alnylam Pharmaceuticals in Q3 2022, an estimated $3.11B increase.
- Nuveen's biggest Q3 2022 reduction was Alphabet (Google) Class A, cutting an estimated $343M.
- Nuveen fully exited Atlassian in Q3 2022, selling an estimated $82.9M.
- Nuveen's ten largest holdings make up 22% of its $247B portfolio in Q3 2022.
- Nuveen opened 107 new positions and closed 58 in Q3 2022.
- Nuveen's portfolio value fell 4.5% quarter-over-quarter to $247B.
Based on Nuveen's 13F filing for Q3 2022, filed 14 Nov 2022.